HCM
EGRX

Highbridge Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Highbridge Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-15,700
Closed -$937K – 2033
2017
Q3 		$937K Buy
+15,700
New +$950K 0.01% 616

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Highbridge Capital Management's EGRX Position: Q4 2015 in Review

Highbridge Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2015, closing a stake of 38,743 shares — an estimated $2.87M sold.

Highbridge Capital Management first reported a position in EGRX in Q2 2015 and held it in 2 quarters. The position peaked at $4.19M in Q2 2015. 133 funds tracked by Wall St. Rank hold EGRX as of Q4 2015.

  • Highbridge Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • Highbridge Capital Management sold 38,743 Eagle Pharmaceuticals, Inc. shares in Q4 2015, an estimated $2.87M.
  • Highbridge Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 2 quarters.
  • Highbridge Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $4.19M in Q2 2015.
  • 133 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2015.

Based on Highbridge Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.